This highlights the importance of precise molecular segregation of NB patients before testing MEK1/2-inhibition in combination with other therapies, and illustrates the key role of distinct ERK kinases in mediating the efficacy of MEK1/2 inhibitors in NB. Here, MAP2K1 is linked to neuroblastoma.